The FDA approved pegunigalsidase alpha (Elfabrio, Chiesi, Protalix BioTherapeutic), on 5/10/2023, for the treatment of adult patients with Fabry disease. Pegunigalsidasealpha was approved with a boxed waring regarding hypersensitivity reactions, including anaphylaxis.
The FDA approved fezolinetant (Veozah,Astellas Pharma), on 5/12/2023, to treat moderate to severe vasomotor symptoms caused by menopause. Astellas priced fezolinetant a t$6,600 per year, which is higher than the $2,000 to $2,500 range recommended byICER.
The FDA rejected N-803 plus BacillusCalmette-Guerin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder carcinoma due to manufacturing deficiencies.
The FDA rejected trastuzumab duocarmazine for the treatment of pretreated HER2-positive unresectable locally advanced or metastatic breast cancer and requested additional unspecified information.
An FDA review of delandistrogene moxeparvovec questioned whether microdystrophin protein expressionis a valid surrogate endpoint that can be used for approval, since microdystrophin has not demonstrated a pharmacologic effect on a biomarker in the pathway of the disease. The FDA failed to find a benefit for ambulatory DMD patients in a review of delandistrogene moxeparvovectrials. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 to recommend approval of delandistrogene moxeparvovec.
The FDA designated ampreloxetine an Orphan Drug for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy.
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right